Skip to main content

Table 3 Site variability in outcomes (adjusted for differences in patient case mix)

From: Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

 

Median (Q1, Q3) site-level baseline hazard estimate

p-value for non-zero variance

Death or lung transplant

0.98 (0.92, 1.11)

0.28

Hospitalization

1.06 (0.77, 1.30)

0.052

Decline in FVC ≥ 10% (mL) or death or lung transplant

0.99 (0.94, 1.03)

0.29

Decline in FVC ≥ 10% predicted or death or lung transplant

1.00 (0.97, 1.02)

0.52

Decline in DLco ≥ 15% (mmol/min/kPa) or death or lung transplant

0.97 (0.94, 1.07)

0.11

Decline in DLco ≥ 15% predicted or death or lung transplant

0.99 (0.90, 1.13)

0.12

Increase in SGRQ total score ≥ 7 or death or lung transplant

0.99 (0.98, 1.01)

0.48

Increase in SGRQ activity score ≥ 5 or death or lung transplant

0.99 (0.97, 1.03)

0.40

Increase in SGRQ impact score ≥ 7 or death or lung transplant

0.99 (0.97, 1.01)

0.40

Increase in SGRQ symptoms score ≥ 8 or death or lung transplant

0.99 (0.91, 1.02)

0.20

Decrease in CASA-Q cough impact domain ≥ 11 or death or lung transplant

0.99 (0.94, 1.05)

0.23

Decrease in CASA-Q cough symptoms domain ≥ 11 or death or lung transplant

0.98 (0.91, 1.06)

0.13

Decrease in EuroQoL-5D index score ≥ 0.06 or death or lung transplant

1.00 (0.98, 1.01)

0.72

Decrease in EuroQoL-5D VAS score ≥ 8 or death or lung transplant

1.00 (0.97, 1.03)

0.60

Decrease in SF-12 MCS score ≥ 6 or death or lung transplant

0.99 (0.95, 1.05)

0.32

Decrease in SF-12 PCS score ≥ 5 or death or lung transplant

0.99 (0.98, 1.01)

0.54